Taletrectinib Clinical Trials

3 actively recruiting trials across 1 location

No change since May 2026

Also known as: AB-106, DS-6051b

Pipeline

Phase 3: 2

Top Sponsors

Nuvation Bio Inc.2
Innovent Biologics (Suzhou) Co. Ltd.1

Indications

Lung Cancer3
Cancer3
Non Small Cell Lung Cancer2
Non-small Cell Lung Cancer (NSCLC)1

Other2 trials

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

Phase 3

Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases

Los Angeles, California1 trial

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

UCLA

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.